Pharmaceutical

Teva and mAbxience partner to develop biosimilar candidate for oncology

Teva Pharmaceuticals International and mAbxience have entered into a worldwide licencing agreement to develop an anti programmed cell death protein 1 oncology biosimilar candidate.

Oct 6, 2024 - 04:00
Teva and mAbxience partner to develop biosimilar candidate for oncology
Teva Pharmaceuticals International and mAbxience have entered into a worldwide licencing agreement to develop an anti programmed cell death protein 1 oncology biosimilar candidate.
Read the original article

Tags:

Previous Article

Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo

Next Article

BMS receives FDA approval for Opdivo to treat NSCLC

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Ohio has enshrined the right to an abortion. But major obstacles remain for patients and providers

Opinion: Ohio has enshrined the right to an abortion. B...

Nov 13, 2023

DF-003 by Drug Farm for Chronic Kidney Disease (Chronic...

Oct 29, 2023

STAT+: Pharmalittle: We’re reading about RSV vax link to GSB, a Pfizer donation, and more

STAT+: Pharmalittle: We’re reading about RSV vax link t...

Mar 2, 2024